Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2001 Apr;70(4):494–499. doi: 10.1136/jnnp.70.4.494

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

M Sormani 1, D Miller 1, G Comi 1, F Barkhof 1, M Rovaris 1, P Bruzzi 1, M Filippi 1
PMCID: PMC1737302  PMID: 11254773

Abstract

OBJECTIVE—A new parametric simulation procedure based on the negative binomial (NB) model was used to evaluate the sample sizes needed to achieve optimal statistical powers for parallel groups (with (PGB) and without (PG) a baseline correction scan). It was also used for baseline versus treatment (BVT) design clinical trials in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS), when using the number of new enhancing lesions seen on monthly MRI of the brain as the measure of outcome.
METHODS—MRI data obtained from 120 untreated patients with RRMS selected for the presence of MRI activity at baseline, 66 untreated and unselected patients with RRMS, and 81 untreated and unselected patients with SPMS were fitted using an NB distribution. All these patients were scanned monthly for at least 6 months and were all from the placebo arms of three large scale clinical trials and one natural history study. The statistical powers were calculated for durations of follow up of 3 and 6months.
RESULTS—The frequency of new enhancing lesions in patients with SPMS was lower, but not significantly different, from that seen in unselected patients with RRMS. As expected, enhancement was more frequent in patients with RRMS selected for MRI activity at baseline than in the other two patient groups. As a consequence, the estimated sample sizes needed to detect treatment efficacy in selected patients with RRMS were smaller than those of unselected patients with RRMS and those with SPMS. Baseline correction was also seen to reduce the sample sizes of PG design trials. An increased number of scans reduced the sample sizes needed to perform BVT trials, whereas the gain in power was less evident in PG and PGB trials.
CONCLUSION—This study provides reliable estimates of the sample sizes needed to perform MRI monitored clinical trials in the major MS clinical phenotypes, which should be useful for planning future studies.



Full Text

The Full Text of this article is available as a PDF (182.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Filippi M., Iannucci G., Tortorella C., Minicucci L., Horsfield M. A., Colombo B., Sormani M. P., Comi G. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology. 1999 Feb;52(3):588–594. doi: 10.1212/wnl.52.3.588. [DOI] [PubMed] [Google Scholar]
  2. Kappos L., Moeri D., Radue E. W., Schoetzau A., Schweikert K., Barkhof F., Miller D., Guttmann C. R., Weiner H. L., Gasperini C. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999 Mar 20;353(9157):964–969. doi: 10.1016/s0140-6736(98)03053-0. [DOI] [PubMed] [Google Scholar]
  3. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  4. Li D. K., Paty D. W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999 Aug;46(2):197–206. doi: 10.1002/1531-8249(199908)46:2<197::aid-ana9>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  5. McFarland H. F., Frank J. A., Albert P. S., Smith M. E., Martin R., Harris J. O., Patronas N., Maloni H., McFarlin D. E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992 Dec;32(6):758–766. doi: 10.1002/ana.410320609. [DOI] [PubMed] [Google Scholar]
  6. Miller D. H., Albert P. S., Barkhof F., Francis G., Frank J. A., Hodgkinson S., Lublin F. D., Paty D. W., Reingold S. C., Simon J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol. 1996 Jan;39(1):6–16. doi: 10.1002/ana.410390104. [DOI] [PubMed] [Google Scholar]
  7. Miller D. H., Barkhof F., Nauta J. J. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain. 1993 Oct;116(Pt 5):1077–1094. doi: 10.1093/brain/116.5.1077. [DOI] [PubMed] [Google Scholar]
  8. Miller D. H., Molyneux P. D., Barker G. J., MacManus D. G., Moseley I. F., Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol. 1999 Dec;46(6):850–859. doi: 10.1002/1531-8249(199912)46:6<850::aid-ana7>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  9. Molyneux P. D., Filippi M., Barkhof F., Gasperini C., Yousry T. A., Truyen L., Lai H. M., Rocca M. A., Moseley I. F., Miller D. H. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol. 1998 Mar;43(3):332–339. doi: 10.1002/ana.410430311. [DOI] [PubMed] [Google Scholar]
  10. Nauta J. J., Thompson A. J., Barkhof F., Miller D. H. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci. 1994 Mar;122(1):6–14. doi: 10.1016/0022-510x(94)90045-0. [DOI] [PubMed] [Google Scholar]
  11. Paolillo A., Coles A. J., Molyneux P. D., Gawne-Cain M., MacManus D., Barker G. J., Compston D. A., Miller D. H. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology. 1999 Sep 11;53(4):751–757. doi: 10.1212/wnl.53.4.751. [DOI] [PubMed] [Google Scholar]
  12. Rovaris M., Filippi M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol. 1999 Jun;12(3):337–344. doi: 10.1097/00019052-199906000-00012. [DOI] [PubMed] [Google Scholar]
  13. Simon J. H., Jacobs L. D., Campion M., Wende K., Simonian N., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol. 1998 Jan;43(1):79–87. doi: 10.1002/ana.410430114. [DOI] [PubMed] [Google Scholar]
  14. Sorensen P. S., Wanscher B., Jensen C. V., Schreiber K., Blinkenberg M., Ravnborg M., Kirsmeier H., Larsen V. A., Lee M. L. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998 May;50(5):1273–1281. doi: 10.1212/wnl.50.5.1273. [DOI] [PubMed] [Google Scholar]
  15. Sormani M. P., Bruzzi P., Miller D. H., Gasperini C., Barkhof F., Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci. 1999 Feb 1;163(1):74–80. doi: 10.1016/s0022-510x(99)00015-5. [DOI] [PubMed] [Google Scholar]
  16. Sormani M. P., Molyneux P. D., Gasperini C., Barkhof F., Yousry T. A., Miller D. H., Filippi M. Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):465–469. doi: 10.1136/jnnp.66.4.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tortorella C., Viti B., Bozzali M., Sormani M. P., Rizzo G., Gilardi M. F., Comi G., Filippi M. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology. 2000 Jan 11;54(1):186–193. doi: 10.1212/wnl.54.1.186. [DOI] [PubMed] [Google Scholar]
  18. Truyen L., Barkhof F., Tas M., Van Walderveen M. A., Frequin S. T., Hommes O. R., Nauta J. J., Polman C. H., Valk J. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials. Mult Scler. 1997 Jan;2(6):283–290. doi: 10.1177/135245859700200604. [DOI] [PubMed] [Google Scholar]
  19. Tubridy N., Ader H. J., Barkhof F., Thompson A. J., Miller D. H. Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):50–55. doi: 10.1136/jnnp.64.1.50. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES